Sol-Gel Technologies (SLGL) Competitors $0.55 +0.07 (+14.58%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.53 -0.02 (-4.36%) As of 04/17/2025 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLGL vs. CTOR, BYSI, ACRV, DTIL, IMRX, BLUE, SCLX, NBRV, IMMX, and QNCXShould you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include Citius Oncology (CTOR), BeyondSpring (BYSI), Acrivon Therapeutics (ACRV), Precision BioSciences (DTIL), Immuneering (IMRX), bluebird bio (BLUE), Scilex (SCLX), Nabriva Therapeutics (NBRV), Immix Biopharma (IMMX), and Quince Therapeutics (QNCX). These companies are all part of the "pharmaceutical products" industry. Sol-Gel Technologies vs. Citius Oncology BeyondSpring Acrivon Therapeutics Precision BioSciences Immuneering bluebird bio Scilex Nabriva Therapeutics Immix Biopharma Quince Therapeutics Citius Oncology (NASDAQ:CTOR) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking. Is CTOR or SLGL more profitable? Citius Oncology has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -81.75%. Sol-Gel Technologies' return on equity of -27.17% beat Citius Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Citius OncologyN/A -43.67% -9.74% Sol-Gel Technologies -81.75%-27.17%-22.49% Do analysts rate CTOR or SLGL? Citius Oncology presently has a consensus target price of $3.00, suggesting a potential upside of 346.50%. Sol-Gel Technologies has a consensus target price of $5.00, suggesting a potential upside of 809.09%. Given Sol-Gel Technologies' higher probable upside, analysts plainly believe Sol-Gel Technologies is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Sol-Gel Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of CTOR or SLGL? 70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 4.6% of Citius Oncology shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, CTOR or SLGL? Citius Oncology has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Does the MarketBeat Community believe in CTOR or SLGL? Sol-Gel Technologies received 148 more outperform votes than Citius Oncology when rated by MarketBeat users. However, 100.00% of users gave Citius Oncology an outperform vote while only 63.40% of users gave Sol-Gel Technologies an outperform vote. CompanyUnderperformOutperformCitius OncologyOutperform Votes1100.00% Underperform VotesNo VotesSol-Gel TechnologiesOutperform Votes14963.40% Underperform Votes8636.60% Which has better earnings & valuation, CTOR or SLGL? Citius Oncology has higher earnings, but lower revenue than Sol-Gel Technologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius OncologyN/AN/A-$21.15MN/AN/ASol-Gel Technologies$11.71M1.31-$27.24M-$0.34-1.62 Does the media prefer CTOR or SLGL? In the previous week, Sol-Gel Technologies had 3 more articles in the media than Citius Oncology. MarketBeat recorded 3 mentions for Sol-Gel Technologies and 0 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.00 equaled Sol-Gel Technologies'average media sentiment score. Company Overall Sentiment Citius Oncology Neutral Sol-Gel Technologies Neutral SummarySol-Gel Technologies beats Citius Oncology on 8 of the 13 factors compared between the two stocks. Get Sol-Gel Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLGL vs. The Competition Export to ExcelMetricSol-Gel TechnologiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.37M$6.44B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.31%P/E Ratio-1.626.8821.7317.77Price / Sales1.31231.02379.1697.65Price / CashN/A65.6738.2234.64Price / Book0.335.916.443.98Net Income-$27.24M$142.72M$3.21B$247.44M7 Day Performance27.91%4.33%2.82%1.82%1 Month Performance-1.26%-12.80%-8.67%-6.98%1 Year Performance-41.77%-9.71%11.32%1.49% Sol-Gel Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLGLSol-Gel Technologies1.9927 of 5 stars$0.55+14.6%$5.00+809.1%-35.8%$15.32M$11.71M-1.6250News CoverageGap UpHigh Trading VolumeCTORCitius OncologyN/A$0.66-1.1%$3.00+351.9%N/A$47.50MN/A0.00N/AGap UpBYSIBeyondSpringN/A$1.17+6.4%N/A-29.2%$47.17M$1.88M0.0080Gap DownACRVAcrivon Therapeutics1.7431 of 5 stars$1.50-7.4%$23.17+1,444.4%-82.5%$47.03MN/A-0.5658Short Interest ↑DTILPrecision BioSciences3.5405 of 5 stars$4.46+1.4%$37.67+744.5%-56.4%$46.75M$68.70M74.35200Short Interest ↑IMRXImmuneering3.3228 of 5 stars$1.30+0.8%$12.50+861.5%-31.7%$46.65M$320,000.00-0.6660Short Interest ↓Gap UpBLUEbluebird bio2.5959 of 5 stars$4.76-7.6%$44.60+837.0%-78.5%$46.60M$83.81M-0.13520SCLXScilex1.9816 of 5 stars$0.19-3.9%$13.00+6,796.6%-85.3%$45.87M$56.59M-0.2380Stock SplitNews CoverageNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070IMMXImmix Biopharma2.2621 of 5 stars$1.63+4.2%$7.00+329.4%-33.6%$45.19MN/A-1.929Positive NewsGap UpQNCXQuince Therapeutics2.066 of 5 stars$1.02+2.0%$8.00+684.3%-0.9%$44.88MN/A-0.8260Gap Down Related Companies and Tools Related Companies Citius Oncology Alternatives BeyondSpring Alternatives Acrivon Therapeutics Alternatives Precision BioSciences Alternatives Immuneering Alternatives bluebird bio Alternatives Scilex Alternatives Nabriva Therapeutics Alternatives Immix Biopharma Alternatives Quince Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLGL) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sol-Gel Technologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sol-Gel Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLGL Stock Free SLGL Stock Alerts